In breve
Questo articolo riassume i trial clinici che studiano Lutetium (177Lu) Oxodotreotide in diversi tumori. I trial valutano soprattutto efficacia, sicurezza, tollerabilità e dosimetria, cioè quanta radiazione raggiunge gli organi e i tumori. Le popolazioni includono adulti, adolescenti e bambini con tumori neuroendocrini e altre neoplasie selezionate.
Punti chiave
- Gli studi su Lutetium (177Lu) Oxodotreotide riguardano soprattutto tumori neuroendocrini, ma anche meningioma, neuroblastoma e carcinoma polmonare a piccole cellule in stadio esteso. I trial sono in fase 1, 2 e 3, quindi includono sia studi iniziali su dose e sicurezza sia studi più grandi su efficacia. Molti studi arruolano pazienti con tumori SSTR positivi, cioè con recettori della somatostatina. Gli obiettivi più comuni sono sopravvivenza libera da progressione, controllo di malattia, sopravvivenza globale e risposta del tumore. Alcuni trial valutano anche la tossicità ematologica, la dosimetria e la qualità di vita. In diversi studi Lutetium (177Lu) Oxodotreotide viene confrontato con la sorveglianza attiva o con cure standard.
Overview of the trial program
The trial data show a broad research program for Lutetium (177Lu) Oxodotreotide, with studies in neuroendocrine tumors, meningioma, neuroblastoma, and extensive-stage small cell lung cancer. Most studies are interventional, which means the researchers give a treatment and then measure what happens.
Across the trials, the main goals are to study efficacy, safety, tolerability, and radiation dose to organs and tumors. Several studies compare Lutetium (177Lu) Oxodotreotide with standard care, active surveillance, or other treatment strategies.
Who is being studied
The largest group of trials includes patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including advanced disease, well-differentiated tumors, and tumors with somatostatin receptor positivity. Some studies focus on midgut neuroendocrine tumors, small intestinal neuroendocrine neoplasms, or patients with liver metastases.
Other studies include people with recurrent or refractory meningioma, children with recurrent or refractory neuroblastoma, adolescents with GEP-NETs or pheochromocytoma/paraganglioma, and patients with extensive-stage small cell lung cancer. One study also includes children and adolescents with recurrent or relapsed solid tumors that express somatostatin receptors.
Trial phases and study design
The studies span Phase 1, Phase 2, and Phase 3 research. Phase 1 trials are used mainly to define dose, safety, or tolerability, while Phase 2 and Phase 3 trials look more closely at how well the treatment works in larger groups.
Some studies are randomized, meaning patients are assigned by chance to different treatment groups. Others compare Lutetium (177Lu) Oxodotreotide with active surveillance, best supportive care, or standard treatment choices.
Main endpoints being measured
The most common endpoint is progression-free survival (PFS), which is the time before the cancer gets worse or the patient dies from any cause. One adjuvant study uses relapse-free survival (RFS), which measures time from randomization to relapse or death.
Other studies measure disease control rate, overall survival, response rate, and time to deterioration in health-related quality of life. Safety endpoints include adverse events, serious adverse events, dose-limiting toxicities, laboratory toxicities, and hematologic toxicity.
Some trials also measure absorbed radiation dose in organs such as the kidney and bone marrow, or tumor uptake on imaging tests like PET-CT or SPECT/CT.
Trials by condition
Neuroendocrine tumors are the main focus of the trial program. Several Phase 3 studies test Lutetium (177Lu) Oxodotreotide as first-line treatment in advanced GEP-NETs or as part of treatment strategies after progression. Other studies look at retreatment, adjuvant use after surgery for stage III small intestinal disease, or less intensive schedules for slowly progressive midgut tumors.
For meningioma, the trials ask whether Lutetium (177Lu) Oxodotreotide can help control recurrent or refractory disease, including grades 2 and 3. The main outcomes here are progression-free survival, often assessed by MRI-based criteria.
In children and adolescents, the studies include recurrent or refractory neuroblastoma and other relapsed solid tumors with somatostatin receptor expression. These trials focus on finding the maximum tolerated dose, early response, safety, and quality of life.
One study in extensive-stage small cell lung cancer examines Lutetium (177Lu) Oxodotreotide with carboplatin, etoposide, and atezolizumab, first to define the dose and then to test overall survival.
What these studies may mean for patients
These trials show that Lutetium (177Lu) Oxodotreotide is being tested in both earlier and more advanced research settings. Some studies ask whether it should be used earlier in treatment, while others test whether it can help after disease progression or in special groups such as children and adolescents.
For patients, the key point is that trial participation depends on the cancer type, tumor features such as somatostatin receptor positivity, age group, and previous treatment history. The studies are designed to answer practical questions about benefit, safety, and how to measure response in different diseases.